Document ID: chunk:federal_register_of_legislation:F2024L01732:schedule:1
Version: federal_register_of_legislation:F2024L01732
Segment Type: schedule
Provision Reference: sch 1
Character Range: 2184–3831

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

     1.            Schedule 1, entry for Acalabrutinib
         omit:
   Capsule 100 mg  20  56  5

     1.            Schedule 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium trihydrate)
    omit from the column headed "Form": Tablet (enteric coated) 20 mg (as magnesium trihydrate)
    substitute: Tablet (enteric coated) 20 mg (as magnesium)
     1.            Schedule 1, entry for Esomeprazole in the form Tablet (enteric coated) 40 mg (as magnesium trihydrate)
    omit from the column headed "Form": Tablet (enteric coated) 40 mg (as magnesium trihydrate)
    substitute: Tablet (enteric coated) 40 mg (as magnesium)
     1.            Schedule 1, after entry for Tafamidis
         insert:
Talazoparib  Capsule 100 micrograms (as tosilate)  20  30  5
             Capsule 250 micrograms (as tosilate)  20  30  5
             Capsule 350 micrograms (as tosilate)  20  30  5
             Capsule 500 micrograms (as tosilate)  20  30  5

     1.            Schedule 2, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium trihydrate)
    omit from the column headed "Form": Tablet (enteric coated) 20 mg (as magnesium trihydrate)
    substitute: Tablet (enteric coated) 20 mg (as magnesium)
     1.            Schedule 2, entry for Esomeprazole in the form Tablet (enteric coated) 40 mg (as magnesium trihydrate)
    omit from the column headed "Form": Tablet (enteric coated) 40 mg (as magnesium trihydrate)
    substitute: Tablet (enteric coated) 40 mg (as magnesium)